Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaNeil P. Shah, Charles L. Sawyers, John Nicoll et al.|Cancer Cell|2002Cited by 1.6k
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrđan Verstovšek, H. Kantarjian, Vikas Gupta et al.|Haematologica|2013Cited by 162